Nicolas Barthelemy

Plasma eMTBR-tau243 and %p-tau217 for Biological Staging of Alzheimer Disease Supplement 1. eTable 1. Demographic Characteristics of Knight ADRC Participants eTable 3. Confusion Matrices of Plasma-Based Stages Against PET-Based Stages in Each Subsample eTable 4. Statistics PET-Based Stages vs Plasma-Based Stages eTable 5. Cross-Sectional Differences in AD Biomarkers in BioFINDER-2 eTable 6. Differences in Longitudinal Changes in AD Biomarkers in BioFINDER-2 eTable 7.

Abstract To efficiently implement plasma and cerebrospinal fluid (CSF) biomarkers for staging and prognosis of Alzheimer disease (AD), we must understand their dynamics across disease progression. We analyzed participants from the Swedish BioFINDER-2 study with mass spectrometry measurements of plasma and CSF tau species, including eMTBR-tau243/MTBR-tau243 and phosphorylation occupancies (%p-tau). Disease duration was estimated using Aβ-PET and tau-PET with the SILA algorithm.

Neurofilaments (NFs) are key cytoskeletal proteins that regulate axon integrity.1 NFs are primarily expressed in neurons and are represented by three subunits: neurofilament light (NfL), neurofilament medium (NfM), and neurofilament heavy (NfH) that complex with α-internexin in the central nervous system (CNS) or peripherin in the peripheral nervous system (PNS).